- Home
- PLUG vs CPRX Comparison
PLUG vs CPRX Comparison
Compare PLUG & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PLUG | CPRX |
|---|---|---|
| Founded | 1997 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.9B |
| IPO Year | 1999 | 2006 |
Fundamental Metrics
Financial Performance| Metric | PLUG | CPRX |
|---|---|---|
| Price | $2.18 | $31.49 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 1 |
| Target Price | $2.31 | ★ $35.00 |
| AVG Volume (30 Days) | ★ 46.2M | 1.9M |
| Earning Date | 05-11-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 47.01 | 28.24 |
| EPS | N/A | ★ 0.50 |
| Revenue | ★ $709,919,000.00 | $119,072,803.00 |
| Revenue This Year | $26.67 | $9.20 |
| Revenue Next Year | $8.09 | $10.51 |
| P/E Ratio | ★ N/A | $62.96 |
| Revenue Growth | 12.90 | ★ 16.39 |
| 52 Week Low | $1.39 | $19.05 |
| 52 Week High | $4.58 | $32.56 |
Technical Indicators
Market Signals| Indicator | PLUG | CPRX |
|---|---|---|
| Relative Strength Index (RSI) | 26.14 | 69.77 |
| Support Level | $2.11 | $31.25 |
| Resistance Level | $2.52 | $32.56 |
| Average True Range (ATR) | 0.18 | 0.04 |
| MACD | -0.02 | -0.06 |
| Stochastic Oscillator | 5.67 | 84.61 |
Price Performance
Historical ComparisonAbout PLUG Plug Power Inc.
Plug Power Inc is building an end-to-end green hydrogen ecosystem, from production, storage, and delivery to energy generation. The company plans to build and operate green hydrogen highways across North America and Europe. Plug will deliver its green hydrogen solutions directly to its customers and through joint venture partners into multiple end markets, including material handling, e-mobility, power generation, and industrial applications.
About CPRX Catalyst Pharmaceuticals Inc.
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.